Concepedia

Mustapha Chadjaa

MC

Statistics

Publications

16

Citations

1.1K

H-Index

14

Active since

2014

Affiliations

Sanofi (France)(Current)

Institut Gustave Roussy

Université Paris-Sud

Vall d'Hebron Institute of Oncology

Hôpital Européen Georges-Pompidou

Mustapha Chadjaa is an author at Sanofi (France) specializing in oncology, pharmacology, and medicine.

ORCID

Publications per year

2014–2023

16

Publications

16

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA

Stéphane Oudard, Karim Fizazi, Lisa Sengeløv et al. · Journal of Clinical Oncology · 2017 · 356 citations

, , +17

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m<sup>2</sup>) and the Currently Approved Dose (25 mg/m<sup>2</sup>) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Choung‐Soo Kim et al. · Journal of Clinical Oncology · 2017 · 289 citations

, , +17

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

Niven Mehra, David Dolling, Semini Sumanasuriya et al. · European Urology · 2018 · 110 citations · Full text

, , +17

Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA

Semini Sumanasuriya, George Seed, Harry Parr et al. · European Urology · 2021 · 65 citations · Full text

, , +17

Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).

Oliver Sartor, Stéphane Oudard, Lisa Sengeløv et al. · Journal of Clinical Oncology · 2016 · 53 citations

, , +17

1–5 of 16